By Keith L. Carson
Volume 7, Issue 1 (Spring 2008)
Today, thanks to the continued pace of M&As, there are fewer biotech companies, and the desired number of new products just hasn’t materialized. But the real travesty is the loss of the small companies that were creating so many of the highly skilled jobs, and providing the innovation that was driving much of the industry. And what happened to all the displaced workers? Instead of forming partnerships to capitalize on the benefits these small companies had to offer, the acquiring companies had to have it all, or nothing. And unfortunately, too many of them ended up with nothing…
Citation: Carson KL. From the Publisher: Fewer Biologics Companies and the Desired Number of New Products Hasn’t Materialized. BioProcess J, 2008; 7(1): 6. https://doi.org/10.12665/J71.KCarson
Posted online July 27, 2026